Save the date!
Aerosol School 2020 will be held at the University of Alberta in Edmonton, Alberta, Canada, from Sep. 23-25, 2020
Click to learn more

Faculty Bios

Myrna Dolovich is Professor of Medicine (Part-time) in the Faculty of Health Sciences, McMaster University, Hamilton, Ontario and associated with the Firestone Institute of Respiratory Health. She is an Electrical Engineer (McGill University, 1963) and worked initially in research in the Cardio-Respiratory Department at the Royal Victoria Hospital in Montreal, joining McMaster University in 1968. Her research at McMaster involves inhaler characterization and performance, investigations into the behaviour of therapeutic aerosols in patients with asthma and COPD with special interest in the measurement of drug delivery to the lung using 2D Planar and 3D PET imaging. Current work involves investigations of the delivery of vaccine aerosols as well as the function of ciliated epithelial cells in COPD. She was involved in the design and characterization of the Aerochamber™, a holding chamber spacer device for pressurized inhalers used worldwide by patients with respiratory disease. She has published 140 book chapters and peer-reviewed papers in the medical literature and has spoken extensively on pulmonary drug delivery systems and imaging. She currently serves as Chair of the Canadian Standards Association (CSA) Technical Sub-Committee, the group that prepared the national standard for spacers (CAN/CSA Z264.1-02:2002) and other drug delivery devices. She is also Head of the Canadian Delegation to the Canadian Advisory Council for the ISO Technical Committee 84 that developed the standards for aerosol drug delivery devices (ISO 27427, ISO 20072). She is a member of the Health Canada Scientific Advisory Committee for Respiratory and Allergy Therapies (SAC-RAT) and has served on the Board of Directors of the International Society for Aerosols in Medicine (ISAM). Currently, she is a member of the Editorial Boards of the Journal of Aerosols in Medicine Pulmonary Drug Delivery and Pediatric Allergy, Asthma and Immunology. In 2006, she was awarded the AAAR/ISAM Thomas T Mercer Prize and in 2009, the ISAM Career Achievement Award. An ISAM Student Travel Award has been established in her name. She has organized and co-chaired 4 international meetings on drug delivery devices under the DIA umbrella and also for the AARC. In 2009, she arranged a 2-day teaching program for practical laboratory experience in aerosol basics, aerosol measurements and techniques, including applications to research and pharmaceutical laboratory and clinical settings. With contributions from the Aerosol School faculty, the program has been expanded and will be held for the 12th year in 2020.

mdolovic@mcmaster.ca

Adrian Goodey is a Principal Scientist in the Biopharmaceutics & Specialty Dosage Forms department of Merck Research Laboratories. In this role, Dr. Goodey has led analytical activities for a number of both early and late stage inhalation, nasal and long-acting parenteral product development teams. Prior to joining Schering-Plough in 2007, Dr. Goodey earned a B.Sc. in chemistry from Emory University, completed a Ph.D. in chemistry at the University of Texas at Austin, and then served as an American Chemical Society/ Petroleum Research Fund Alternative Energy Postdoctoral Fellow at the Pennsylvania State University. Dr. Goodey currently chairs the IPAC-RS Cascade Impaction working group. His research interests include the analysis of cascade impaction data, automation of inhaler testing and clinically relevant testing. To date, he has authored eighteen peer reviewed scientific articles and holds two patents.

Adrian.goodey@merck.com

Philip Kuehl is a Senior Scientist and Director of Scientific Core Laboratories at Lovelace Biomedical in Albuquerque, NM. He holds a bachelor’s degree in biochemistry from Hamline University in St. Paul, MN and a PhD in Pharmaceutical Sciences from The University of Arizona, College of Pharmacy in Tucson Arizona. Dr. Kuehl is an Adjunct Professor at the University of New Mexico College of Pharmacy.

Dr. Kuehl’s research interests are in the area of inhalation formulation and its effects on deposition, pharmacokinetics and pharmacodynamics. Philip is involved in the development of respiratory therapies to include small molecules, proteins, peptides, mRNA, oligonucleotides and cell/gene therapy products. He is currently member of the International Society for Aerosols in Medicine (congress president in 2017), American Association of Pharmaceutical Scientists, Inhalation and Nasal Technology Focus Group, Association of Inhalation Toxicologists, and American Chemical Society. Philip serves on the editorial board for the Journal of Aerosol Medicine and Pulmonary Drug Delivery and as an ad-hoc reviewer for several inhalation and pharmaceutical science based journals.

Lei is a Director of Inhalation Science and Product Development at Recipharm Laboratories based in the Research Triangle Park, North Carolina, US where he heads the inhalation/formulation group supporting inhaled and other dosage form development. Prior to joining Recipharm, Lei worked as a manager in the Pulmonary and Nasal Department at Catalent Pharm Solutions, US (2008-2018), a principal scientist and team leader at Vectura plc, UK (1998-2007) and a section head at IVAX, UK (1996-1998). Over last twenty years, Lei has headed the development function for inhaled dosage forms including complex metered dose inhalers, dry powder inhalers, nebulizers and Softmist inhalers and supported launching of inhalation products in the US market. Lei head the R&D function in an IVAX’s joint-venture in China until started to work in UK in 1996.

Lei’s has over twenty year experience in formulation and inhalation product development in pharmaceutical industry, presents and publishes extensively in conferences, webinars, book chapters, peer reviewed journals and conference proceedings. He is a named inventor for several techniques published in fourteen patents granted worldwide.

He received a Pharmacy degree from China Pharmaceutical University and a Ph.D. in Pharmaceutical Sciences from Shenyang Pharmaceutical University, China.

Jolyon Mitchell operates his own private consultancy business, Jolyon Mitchell Inhaler Consulting Services Inc., from London Ontario Canada. He has been an adjunct professor at the University of Western Ontario since 2006. He is also an affiliate professor at the Daniel K. Inouye College of Pharmacy of the University of Hawai’i (Hilo Campus), where he taught an elective postgraduate course on medical aerosol physics in early 2015.

Until October 2013, he was Scientific Director of Trudell Medical International, with responsibility for all aspects of in vitro aerosol testing. He is involved in several industry-wide organizations involved with inhaled medical aerosol delivery, in particular the European Pharmaceutical Aerosol Group (EPAG) as well as serving as Scientific Adviser to the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). He played a major part in the development of a Canadian Standard for Spacers and Holding Chambers (CAN/CSA Z264.1-02:2002, revised 2008). He is currently a Canadian delegate to ISO/TC121/SC2, having been involved with the development of a standard (ISO 27427) specifically for nebulizers. He also helped develop ISO 20072:2009, a standard for the design and evaluation of the other forms of orally inhaled product.

He is Chair of the Aerosols sub-committee of the General Chapters Committee at the United States Pharmacopeia (2015-2020 session), He is currently completing the development of an informational chapter <1602> covering spacers and valved holding chambers. He is also involved with the development of a potential new chapter covering Good Cascade Impactor Practices for the USP.

He is a Fellow of the UK Royal Society of Chemistry, a Chartered Scientist, a founder member of the UK-Irish Aerosol Society and a member of the Gesellschaft für Aerosolforschung, American Association of Pharmaceutical Scientists (Inhalation Technology Focus Group) and the American Association for Respiratory Care (AARC).

His technical interests are primarily in particle sizing methods, experiment design and data interpretation, as well as inhaler performance characterization in the laboratory using methods that provide clinically meaningful data. He has published more than 450 articles in the open literature, of which about 140 are in peer-reviewed journals and 14 are invited review articles. He is co-editor of a book on Good Cascade Impactor Practice, the Abbreviated Impactor Measurement (AIM) and Effective Data Analysis (EDA) concepts. He has contributed to six books on aerosol science and medical inhalers. He also has an interest in human factors-related aspects of inhaler design, in particular for their use by elderly patients.

mitchelljolyon@gmail.com
Tel: +1-519-472-5364;   Mobile : +1-519-619-4560

Dr. Stapleton is currently an executive with Qrum Pharmaceuticals where he leads the CMC and aerosol development operations. Dr. Stapleton started his career in sales and marketing at Hewlett-Packard (Canada) Ltd. Dr. Stapleton received his Ph.D. from the University of Alberta where he created a Lagrangian dynamical model for predicting the deposition of hygroscopic aerosols in the human respiratory tract, working under the tutelage of Dr. Warren Finlay. In 1996, Dr. Stapleton worked at the Aerosol Research Institute at PARI GmbH where he led the Advanced Platform Development Group which created novel liquid aerosol nebulization systems and a valved holding chamber. In 1998, Dr. Stapleton moved to Advanced Inhalation Research (purchased by Alkermes Inc. in 1999) where he led a group that developed a family of inhalers for delivering the AIR Porous Particles. In 2003, Dr. Stapleton took the position of Director, Inhalation Technology at Corus Pharma Inc. (purchased by Gilead Sciences) where he was responsible for the development of respiratory drug products. Dr. Stapleton was involved in the development of Cayston (aztreonam inhalation solution), from the early formulation development through product approval, launch, and was involved in reimbursement discussions. In 2011, Dr. Stapleton moved to MAP Pharmaceuticals, where he worked on a novel inhaled treatment for migraine. In 2013, MAP was acquired by Allergan Pharmaceuticals, where he continued as CMC team leader for the inhaled migraine program, and was a team member of numerous complex combination projects. Dr. Stapleton joined Qrum Pharmaceuticals in late 2017, and consults with a number of other companies on formulation, device, and aerosol delivery projects.

Andrew Martin, PhD PEng, is an Assistant Professor in Mechanical Engineering at the University of Alberta in Edmonton, Alberta, Canada. He is licensed as a Professional Engineer by the Association of Professional Engineers and Geoscientists of Alberta (APEGA). He completed his PhD in 2008 at the Aerosol Research Laboratory of Alberta (UAlberta). From 2008-2013 he worked in industrial R&D, based first in France and then in the United States, on projects related to medical device development, inhalation drug delivery, and clinical and preclinical programs investigating new applications of therapeutic gases in medicine. In 2014, he returned to the University of Alberta in his current role, where his main research interests are in development and in vitro testing of inhalation drug delivery systems, as well as in the prediction of regional aerosol deposition and clearance within the respiratory tract.

Andrew has published widely on diverse topics related to aerosols in medicine, regularly presents at international conferences, and is lead or co-inventor on several granted and pending patents. In 2013, he received the ISAM Young Investigator Award in recognition of his research contributions. He has served as an ISAM Board Member since 2015, and in the role of General Secretary since 2017. He was a member of the organizing committee for the 2017 ISAM Congress in Sante Fe, and co-organized special symposia on medical aerosols at the 2017 American Association for Aerosol Research Annual Conference in Raleigh and at the 2018 International Aerosol Conference in Saint Louis. He currently serves on the Editorial Board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery.